Sanders Morris Harris LLC Takes $825,000 Position in Thermo Fisher Scientific Inc. $TMO

Sanders Morris Harris LLC purchased a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 1,700 shares of the medical research company’s stock, valued at approximately $825,000.

Several other hedge funds also recently made changes to their positions in TMO. Mirador Capital Partners LP increased its position in Thermo Fisher Scientific by 25.1% in the 3rd quarter. Mirador Capital Partners LP now owns 11,240 shares of the medical research company’s stock valued at $5,452,000 after acquiring an additional 2,253 shares during the period. Thrive Wealth Management LLC increased its position in Thermo Fisher Scientific by 4.1% in the 3rd quarter. Thrive Wealth Management LLC now owns 3,510 shares of the medical research company’s stock valued at $1,702,000 after buying an additional 138 shares in the last quarter. Oak Thistle LLC grew its holdings in shares of Thermo Fisher Scientific by 28.2% during the third quarter. Oak Thistle LLC now owns 972 shares of the medical research company’s stock valued at $471,000 after buying an additional 214 shares during the last quarter. WealthBridge Investment Counsel Inc. lifted its stake in Thermo Fisher Scientific by 1.9% during the 3rd quarter. WealthBridge Investment Counsel Inc. now owns 11,950 shares of the medical research company’s stock valued at $5,796,000 after acquiring an additional 225 shares in the last quarter. Finally, ARS Wealth Advisors Group LLC grew its position in Thermo Fisher Scientific by 43.8% in the 3rd quarter. ARS Wealth Advisors Group LLC now owns 25,569 shares of the medical research company’s stock worth $12,402,000 after purchasing an additional 7,787 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $570.07 on Wednesday. The company has a market cap of $214.18 billion, a price-to-earnings ratio of 32.93, a PEG ratio of 4.21 and a beta of 0.90. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. The firm’s fifty day moving average is $567.10 and its 200 day moving average is $494.60. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping the consensus estimate of $5.50 by $0.29. The business had revenue of $11.12 billion during the quarter, compared to the consensus estimate of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The business’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period last year, the company earned $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Monday, December 15th. Thermo Fisher Scientific’s payout ratio is presently 9.94%.

Thermo Fisher Scientific declared that its Board of Directors has initiated a share buyback plan on Thursday, November 6th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical research company to repurchase up to 2.4% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s leadership believes its stock is undervalued.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. JPMorgan Chase & Co. boosted their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research note on Thursday, October 9th. Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, October 25th. Argus increased their target price on Thermo Fisher Scientific from $580.00 to $610.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Royal Bank Of Canada set a $561.00 target price on shares of Thermo Fisher Scientific and gave the stock an “outperform” rating in a report on Tuesday, September 2nd. Finally, TD Cowen raised their target price on shares of Thermo Fisher Scientific from $612.00 to $654.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus target price of $616.60.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 7,250 shares of the company’s stock in a transaction dated Monday, October 27th. The stock was sold at an average price of $566.10, for a total value of $4,104,225.00. Following the completion of the sale, the chief executive officer directly owned 113,762 shares of the company’s stock, valued at $64,400,668.20. This represents a 5.99% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Frederick M. Lowery sold 6,912 shares of the company’s stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $581.94, for a total transaction of $4,022,369.28. Following the transaction, the executive vice president owned 14,367 shares in the company, valued at $8,360,731.98. The trade was a 32.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 149,271 shares of company stock worth $86,507,282 over the last quarter. Corporate insiders own 0.33% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.